Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice.

Raloxifene is a selective estrogen receptor modulator approved for the prevention of osteoporosis in postmenopausal women. It is selective by having estrogen-agonistic effects on bone, vessels and blood lipids while it is antagonistic on mammary and uterine tissue. Our aim was to study the agonistic and antagonistic properties of the raloxifene analogue LY117018 (LY) on uterus, bone, B lymphopoiesis and B cell function. Oophorectomized and sham-operated animals were treated with s.c. injections of equipotent anti-osteoporotic doses of 17beta-estradiol (E2) (0.1 mg/kg) or LY (3 mg/kg) or vehicle as controls. Effects on bone mineral density (BMD) were studied using peripheral quantitative computed tomography, uterine weight was examined, B lymphopoiesis was examined using flow cytometry and B cell function in bone marrow and spleen was studied by the use of an ELISPOT assay. E2 and LY had similar effects on BMD and bone marrow B lymphopoiesis, while LY had a clear antagonistic effect on endogenous estrogen in uterine tissue and no stimulating effect on the frequency of Ig-producing B cells in sham-operated animals. Our results are discussed in the context of estrogen receptor biology, relations between the immune system and bone metabolism and also with respect to the estrogen-mediated effects on rheumatic diseases.

[1]  Carolyn L. Smith,et al.  Molecular perspectives on selective estrogen receptor modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions , 2002, Steroids.

[2]  K. Ikeda,et al.  Generation of Bone‐Resorbing Osteoclasts from B220+ Cells: Its Role in Accelerated Osteoclastogenesis due to Estrogen Deficiency * , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  R. Pacifici,et al.  Up-regulation of TNF-producing T cells in the bone marrow: A key mechanism by which estrogen deficiency induces bone loss in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Kozo Nakamura,et al.  Connection Between B Lymphocyte and Osteoclast Differentiation Pathways1 , 2001, The Journal of Immunology.

[5]  J. Gustafsson,et al.  Role of oestrogen receptors α and β in immune organ development and in oestrogen‐mediated effects on thymus , 2001 .

[6]  J. Gustafsson,et al.  Role of oestrogen receptors alpha and beta in immune organ development and in oestrogen-mediated effects on thymus. , 2001, Immunology.

[7]  H. Carlsten,et al.  Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice. , 2000, Cellular immunology.

[8]  M. van Eickels,et al.  Estrogen Receptor α Rapidly Activates the IGF-1 Receptor Pathway* , 2000, The Journal of Biological Chemistry.

[9]  A. Strasser,et al.  Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. , 2000, Blood.

[10]  M. Martin,et al.  Role of insulin‐like growth factor‐I in regulating estrogen receptor‐α gene expression , 2000 .

[11]  Chisato Miyaura,et al.  Comparative Effects of Estrogen and Raloxifene on B Lymphopoiesis and Bone Loss Induced by Sex Steroid Deficiency in Mice , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  A. Stoica,et al.  Role of insulin-like growth factor-I in regulating estrogen receptor-alpha gene expression. , 2000, Journal of cellular biochemistry.

[13]  M Carlquist,et al.  Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist , 1999, The EMBO journal.

[14]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[15]  C. Ohlsson,et al.  Expression and Localization of Estrogen Receptor‐β in Murine and Human Bone , 1999 .

[16]  M. Østensen.  Sex Hormones and Pregnancy in Rheumatoid Arthritis and Systemic Lupus Erythematosus , 1999 .

[17]  J. Tobias,et al.  High‐Dose Estrogen Induces De Novo Medullary Bone Formation in Female Mice , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  M. Ostensen.  Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus erythematosus. , 1999, Annals of the New York Academy of Sciences.

[19]  C. Ohlsson,et al.  Expression and localization of estrogen receptor-beta in murine and human bone. , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  J. Gustafsson,et al.  The Estrogen Receptor β Subtype: A Novel Mediator of Estrogen Action in Neuroendocrine Systems , 1998, Frontiers in Neuroendocrinology.

[21]  R. Clark,et al.  Regulation of B and T cell development by anterior pituitary hormones , 1998, Cellular and Molecular Life Sciences CMLS.

[22]  R. Jaffe,et al.  Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles. , 1998, The Journal of clinical endocrinology and metabolism.

[23]  C. Christiansen,et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.

[24]  K. Korach,et al.  Tissue Distribution and Quantitative Analysis of Estrogen Receptor-α (ERα) and Estrogen Receptor-β (ERβ) Messenger Ribonucleic Acid in the Wild-Type and ERα-Knockout Mouse. , 1997, Endocrinology.

[25]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[26]  S. Nozawa,et al.  Expression of Estrogen Receptor β in Rat Bone. , 1997, Endocrinology.

[27]  L. Powell-Braxton,et al.  Primary B cell development is impaired in mice with defects of the pituitary/thyroid axis. , 1997, Journal of immunology.

[28]  J. Gustafsson,et al.  Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. , 1997, Endocrinology.

[29]  S. Nozawa,et al.  Expression of estrogen receptor beta in rat bone. , 1997, Endocrinology.

[30]  T. Waldschmidt,et al.  Estrogen Blocks Early T Cell Development in the Thymus , 1996, American journal of reproductive immunology.

[31]  Roberto Pacifici,et al.  Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  H. Bryant,et al.  Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  C. Roberts,et al.  Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. , 1996, Endocrinology.

[34]  M. Sato,et al.  Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. , 1995, The Journal of pharmacology and experimental therapeutics.

[35]  H. Carlsten,et al.  Estrogen induces suppression of natural killer cell cytotoxicity and augmentation of polyclonal B cell activation. , 1994, Cellular immunology.

[36]  S. Nozawa,et al.  Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. , 1994, The Journal of clinical investigation.

[37]  B. Breier,et al.  Radioimmunoassays for IGFs and IGFBPs. , 1994, Growth regulation.

[38]  D. Williams,et al.  Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. , 1994, The Journal of clinical investigation.

[39]  K. Medina,et al.  Suppression of B lymphopoiesis during normal pregnancy , 1993, The Journal of experimental medicine.

[40]  E. Josefsson,et al.  Anti-inflammatory properties of estrogen. I. In vivo suppression of leukocyte production in bone marrow and redistribution of peripheral blood neutrophils. , 1992, Cellular immunology.

[41]  U. Dahlgren,et al.  Effect of oestradiol on the secretory immune system in the rat: an increase in biliary IgM antibodies against a T-cell independent antigen. , 1991, Immunology.

[42]  R. Holmdahl,et al.  Oestrogen is a potent disease accelerator in SLE‐prone MRL lpr/lpr mice , 1990, Clinical and experimental immunology.

[43]  R. Holmdahl,et al.  Oestrogen is a potent immunomodulator of murine experimental rheumatoid disease. , 1989, British journal of rheumatology.

[44]  C. Gretzer,et al.  An immunoenzyme procedure for enumerating fibronectin-secreting cells. , 1984, Journal of immunoassay.

[45]  M. Schneider,et al.  Enhancement of tumor metastasis and suppression of natural killer cell activity by beta-estradiol treatment. , 1983, Journal of immunology.